Clinical Trials on Dermatitis, Photoallergic in Australia

Total 154 results

Eli Lilly and Company

Terminated

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis (ADmIRe)

Atopic Dermatitis

Spain, Puerto Rico, United States, Canada, Japan, Italy, Argentina, Austria, Czechia, France, Germany, Hungary, Mexico
Kymab Limited
Sanofi

Completed

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study (STREAM-AD)

Eczema | Atopic Dermatitis

United States, Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, United Kingdom
Pfizer

Completed

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN)

Atopic Dermatitis

Spain, United States, Taiwan, Germany, China, Hungary, Australia, Czechia, Japan, Latvia, Poland, United Kingdom, Mexico, Italy
Pfizer

Completed

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Atopic Dermatitis

Spain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up)

Atopic Dermatitis

United States, Australia, Belgium, Bulgaria, Canada, China, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwa... and more
Eli Lilly and Company
Dermira, Inc.

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)

Eczema | Atopic Dermatitis

United States, Taiwan, Spain, Australia, Mexico, Canada, Germany, Japan, Brazil, Argentina, Poland, Czechia, France
Astellas Pharma Inc

Completed

Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment

Dermatitis, Atopic

France, Germany, Spain, Belgium, Netherlands, Finland, Austria, United Kingdom, Italy, Czech Republic, Switzerland, Portugal, Denmark
Pfizer

Active, not recruiting

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Dermatitis, Atopic

China, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
Eli Lilly and Company

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)

Eczema | Atopic Dermatitis

United States, Taiwan, Spain, Mexico, Czechia, Brazil, Japan, Australia, Canada, France, Germany, Argentina, Poland
Eli Lilly and Company
Incyte Corporation

Completed

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable (BREEZE-AD4)

Atopic Dermatitis

Belgium, Netherlands, Japan, Spain, Switzerland, United Kingdom, Germany, France, Austria, Russian Federation, Poland, Italy, Brazil, Finland
Amgen

Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Atopic Dermatitis

United States, Japan, Korea, Republic of, Australia, Taiwan, Spain, Switzerland, Germany, Austria, Denmark, Netherlands, Hungary, Czechia, Poland, Brazil, France, Greece, Portugal, Italy, Finland, Argentina, Slovenia, Estonia, United... and more
Amgen

Active, not recruiting

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) (ROCKET-Horizon)

Atopic Dermatitis

United States, Spain, United Kingdom, Korea, Republic of, Australia, Denmark, Germany, Belgium, Canada, Japan, Sweden, Poland, Romania, Estonia, Brazil, Czechia, Portugal, Finland, Mexico, Turkey, South Africa
Alcon Research

Completed

Evaluation of Safety and Tolerability of Investigational Ocular Lubricants

Dry Eye Disease

Australia
Medical University of Vienna

Recruiting

Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients

Dry Eye Syndromes

Austria
Novartis Pharmaceuticals

Terminated

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, United Kingdom, Germany, Hungary, Russian Federation, Taiwan, Belgium, Netherlands, Japan, Austria, Finland, Slovakia, Czechia, Canada, Iceland, Poland
Medical University of Vienna

Completed

Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Local Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers

Dry Eye Syndromes

Austria
Medical University of Vienna

Enrolling by invitation

Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures

Glaucoma | Cataract | Meibomian Gland Dysfunction | Aniridia | Corneal Transplantation | Acanthamoeba Keratitis | Demodicosis | Conjunctival Pathologies

Austria
LEO Pharma

Terminated

A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis (APPLES)

Atopic Dermatitis

United States, Netherlands, United Kingdom, France, Canada, Ireland, Austria, Germany, Poland
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

Spain, Taiwan, United States, Australia, Poland, Germany, Hungary, Bulgaria, Czechia, Japan, Korea, Republic of, Latvia, Canada, United Kingdom, Mexico, Chile, Slovakia, Italy
Dompé Farmaceutici S.p.A
Cross Research S.A.

Completed

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

Dry Eye Syndrome

Austria
Galderma R&D

Completed

A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis

Prurigo Nodularis

United States, Austria, France, Germany, Poland, Korea, Republic of, Switzerland
Almirall, S.A.

Completed

A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine

Eczema | Dermatitis, Atopic

Austria, Belgium, France, Germany, Netherlands, Poland, Spain, United Kingdom
Medical University of Vienna

Completed

Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
LEO Pharma

Recruiting

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)

Chronic Hand Eczema

Spain, France, Belgium, Australia, Canada, Poland, United Kingdom
Gerhard Garhofer
Croma-Pharma GmbH

Completed

Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation

Dry Eye Syndrome

Austria
Medical University of Vienna

Recruiting

Assessment of TFT by OCT in Healthy Subjects and Subjects With DES

Dry Eye Syndromes

Austria
Allergan

Completed

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Dry Eye Syndromes

Canada, Australia
Novaliq GmbH

Completed

Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease

Dry Eye Disease

Austria
Dreamhawk Vision Biotech, Inc.

Completed

Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Dry Eye Disease

Thailand, Australia, Taiwan
Medical University of Vienna

Completed

Clinical Efficacy of Topical Hydrocortisone 0.335% (Softacort®) in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation

Dry Eye

Austria
Medical University of Vienna

Completed

Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects

Dry Eye Syndrome

Austria
Medical University of Vienna

Completed

Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome

Dry Eye Syndrome

Austria
Medical University of Vienna

Recruiting

Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Effect of Single Instillation of Three Different Topical Lubricants on Tear Film Thickness in Patients With Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Withdrawn

Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease

Dry Eye Syndrome

Austria
Medical University of Vienna

Completed

Correlation of Different Signs for Assessment of Dry Eye Syndrome

Dry Eye Syndrome

Austria
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN2)

Prurigo Nodularis

Korea, Republic of, Spain, United States, Poland, Italy, Australia, Austria, Germany, Canada, Switzerland, France, Denmark, Bulgaria
Medical University of Vienna

Withdrawn

Treatment of Dry Eye With Supplements

Dry Eye Syndromes

Austria
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Australia, Canada
Vyne Therapeutics Inc.

Terminated

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Psoriasis | Pruritus | Atopic Dermatitis | Prurigo Nodularis

United States, Austria, Germany, Poland
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Pruritus | Prurigo Nodularis

Austria, Germany, Poland
LEO Pharma

Completed

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Chronic Hand Eczema

France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Canada, Norway, Slovakia
Redwood Pharma AB
Cross Research S.A.

Completed

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Dry Eye Syndromes

Austria, Germany, Hungary
Kiniksa Pharmaceuticals, Ltd.

Completed

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Prurigo Nodularis | Pruritis

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Poland, Taiwan, United Kingdom
Galderma R&D

Completed

An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis

Prurigo Nodularis

United States, Germany, Austria, Canada, Denmark, Hungary, Italy, Poland, Sweden, United Kingdom
Galderma R&D

Active, not recruiting

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Prurigo Nodularis

United States, Belgium, Canada, France, Korea, Republic of, Netherlands, Poland, Spain, Switzerland, Austria, Denmark, Germany, Hungary, Italy, Sweden, United Kingdom

Clinical Trials on Dermatitis, Photoallergic in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations